Results of a clinical study of the efficacy and safety of Panavir® in the treatment of keratoconjunctivitis of adenovirus etiology
Year: 2022, volume 18 Issue: №4 Pages: 662-667
Heading: Тhematic supplement Article type: Original article
Authors: Veselova Е.М., Kamenskikh T.G., Shadenkov D.A., Stovbun S.V., Rusakova N.M., Barabanova L.S.
Organization: N. N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences, Moscow, Russia, National Research Company LLC, Moscow, Russia, Saratov State Medical University
Heading: Тhematic supplement Article type: Original article
Authors: Veselova Е.М., Kamenskikh T.G., Shadenkov D.A., Stovbun S.V., Rusakova N.M., Barabanova L.S.
Organization: N. N. Semenov Federal Research Center for Chemical Physics Russian Academy of Sciences, Moscow, Russia, National Research Company LLC, Moscow, Russia, Saratov State Medical University
Summary:
Abstract. Objective: to analyze the efficacy, safety and tolerability of Panavir® (eye drops 0.004%) in the treatment of keratoconjunctivitis of adenovirus etiology. Material and methods. 216 patients with acute keratoconjunctivitis of adenovirus etiology participated. Group 1 patients received Panavir® 0.004%, group 2 patients received Ophthalmoferon® (interferon alfa-2b). The study included 5 visits. Results. There was a significant decrease in the number of patients with the studied symptoms (conjunctival follicles and hemorrhages, conjunctival edema and hyperemia, subepithelial infiltrates, itching, foreign body sensation, lacrimation and eyelid edema) by day 10 in both groups (p<0.001 when compared with the initial value of the indicator), while in group 1 there was a more pronounced dynamics on the 10th and 15th day of observation when compared with the value of the indicator in patients from group 2 on each day. In group 1, there was an earlier significant disappearance of hemorrhages and conjunctival follicles (by 13.2±1.3 days, in group 2 by 17.0±1.7 days, p<0.001), edema and hyperemia of the conjunctiva (by 13.2±1.3 days, in group 2 — by 18.7±2.5 days, p<0.001), itching in the eyes (by 8.2±1.6 days, in group 2 —by 13.6±3.2 days, p<0.001)and sensation of a foreign body (by 8.0±1.6 days, in group 2 — by 11.2±3.2 days, p=0.035). Conclusion. The conducted clinical study showed the efficacy, safety and good tolerability of Panavir® in comparison with interferon in the treatment of adenovirus keratoconjunctivitis.
Bibliography:
1. Murchison СЕ, Petroll WM, Robertson DM. Infectious keratitis after corneal crosslinking: a systematic review. J Cataract Refract Surg. 2021; 47 (8): 1075-80. DOI: 10.1097/j.jcrs. 0000000000000620.
2. Pellegrini M, Bernabei F, Barbato F, et al. Incidence, risk factors and complications of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Am J Ophthalmol. 2021; (227): 25-34. DOI: 10.1016/j.ajo.2021.02.022.
3. Chigbu Dl, Labib BA. Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist. 2018; (11): 981-93. doi: 10.2147/IDR.S162669.
4. Klimova RR, KushchAA, Fedorova NE, Litvin AA. Effect of Panavir on herpes simplex virus types 1 and 2 proteins synthesis in cell culture. Antibiotics and Chemotherapy. 2009; 54 (3-4): 18-20.
5. Alimbarova LM, Lazarenko AA, KiselevAV, et al. Evaluation of the effectiveness of the use ot Solarium tuberosum shoot extract in experimental ophthalmic herpes. Bulletin of Ophthalmology. 2015; 131; (3): 76.
6. Safronov DYu, Stovbun SV, Kucherov VA, et al. Anti-inflammatory effect of Panavir in model experiments and clinical practice. Bulletin of the Moscow State Regional University. Series: Natural Sciences. 2011; (3): 82-5.
7. Malkhanov VB, Zaynutdinova GKh, Shevchuk NE. The effectiveness of the drug Panavir with anterior uveitis of rheumatic rubric. Annals of Orenburg State University. 2011; 133 (14): 235-8
8. Betoeva IM, Gonobleva TN, Khetagurova LG, Dzaynukov TS. Clinical efficacy in the treatment of Panavir herpes simplex virus. Vladikavkaz Medical Biological Bulletin. 2013; 16 (24-25): 56-9.
9. Stovbun SV, Yakovenko LV The physicochemical basis of the biological activity and pharmacological properties of the antiviral agent Panavir. Moscow University Physics Bulletin. 2014; (6): 101-6.
| Attachment | Size |
|---|---|
| 2022_04-1_662-667.pdf | 365 KB |
Русский
English